Marking a milestone for gene editing

Posted:
10
November 2020

We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001

The therapy provides a potential cure for Transthyretin Amyloidosis (ATTR), a rare and fatal disease which leads to neuropathy and heart failure.

This marks a milestone in the development of a treatment to arrest the progression of ATTR. Intellia’s proprietary non-viral platform utilises lipid nanoparticles designed to deliver a two-part genome editing system to the liver: guide RNA specific to the disease-causing gene and messenger RNA that encodes the Cas9 protein.

Intellia’s President and Chief Executive Officer John Leonard, M.D. stated “With today’s news, we’re entering a new era of potential genome editing cures for patients.”

The first ATTR patient was dosed at Richmond Pharmacology in a first in human study of NTLA-2001 in adults with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN). The trial’s primary objectives are to assess the safety and to determine the right dose of NTLA-2001 to block the production of faulty aTTR that leads to accumulation in tissues causing dysfunction. Patients receive a single dose of NTLA-2001 via intravenous administration and are followed for 3 years.

Jorg Taubel, M.D., the Principal Investigator at Richmond Pharmacology shared “We are excited to work with Julian Gilmore of the National Amyloidosis centre giving the first dose in this globally first study testing what could be the first curative treatment for ATTR using Nobel Prize-winning CRISPR technology.”

The study will enrol up to 38 participants and consist of a single-ascending dose phase in Part 1 and, following the identification of an optimal dose, an expansion cohort in Part 2.

Further details of the study can be found at www.clinicaltrials.gov (NCT04601051).

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

What 20 years of clinical research has taught us about our industry and the future of drug development

June 9, 2021
As Richmond Pharmacology approaches its 20th anniversary our co-founder and CEO reflects on the developments, regulatory changes, and innovations within the life science industry in an article in the PharmaTimes.
Read more

Do we still need challenge trials with COVID-19?

April 21, 2021
Nir Eyal and colleagues suggested that the initiation of COVID-19 challenge trials in response to the UK governments’ call in 2020 remained relevant and important despite the development of approved vaccines and the introduction of an aggressive, UK-wide vaccination policy.
Read more

Novel rate-controlled fentanyl patch shows promise in phase I clinical trial

April 1, 2021
Our expertise in ethnic differences and access to over 12,000 first generation Japanese volunteers accelerated our ability to provide robust clinical trial data to support future applications of new chronic pain medicines to the Japanese drug market.
Read more